Engflag

Gopan

Quick links to important sections

Gopan

Gopan_EN

Method of action: Antiulcer, Drugs For Acid Related Disorders, Proton Pump Inhibitor

Treatment option: Gastroesophageal Reflux Disease, Hypersecretory Conditions, Heartburn, Pathological Hypersecretory Conditions, Reflux, Zollinger-Ellison Syndrome, Esophagitis, Erosive Esophagitis

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gopan

Property Description
Active Ingredient Pantoprazole (INN)
Form Gastro-resistant tablets, Lyophilized powder for injection
Pharmacological Class Proton Pump Inhibitor (PPI)
General Purpose Reduction of excessive gastric acid secretion
Origin Synthetic compound

What Type of Medicine is Gopan (Pantoprazole)?

Gopan is fundamentally defined by its active pharmaceutical ingredient, the synthetic compound Pantoprazole, and is classified as a Proton Pump Inhibitor (PPI). Pantoprazole belongs to the substituted benzimidazole chemical group, a class of compounds recognized for achieving potent acid suppression. This designation confirms its role in managing various acid-related disorders. While Gopan is primarily used as a single-agent formulation (monotherapy), the formulation is positioned for acid control in adult patients. Variants of the Gopan brand may exist as fixed-dose combination products alongside secondary agents like Domperidone or Levosulpiride, which are incorporated to address related issues of impaired digestive tract movement.

Composition and Available Forms of Gopan

The medicine's composition centers on the International Nonproprietary Name (INN) substance, Pantoprazole, typically utilized as the sodium salt. Gopan is primarily available for oral administration as gastro-resistant tablets, also known as delayed-release tablets. This specialized coating is a critical design feature, ensuring that the Pantoprazole is not destroyed by the stomach’s acidic environment and allows the medication to be absorbed correctly. For patients who cannot tolerate oral intake, a sterile lyophilized powder for reconstitution is available for intravenous administration, reflecting pharmaceutical development to meet different patient needs.

General Purpose: What Gopan Helps to Achieve

The overall purpose of Gopan is to achieve the profound reduction of gastric acid secretion by acting directly on the final stage of acid production. Pantoprazole is associated with consistent suppression of gastric acidity. This therapeutic action is intended for alleviating the chronic irritation and burning sensations associated with excessive acid production and establishing a less corrosive environment in the upper gastrointestinal system.

Regulatory References

  1. Pantoprazole Sodium Delayed-Release Tablets (DailyMed)

What side effects are possible with Gopan?

Possible Side Effects and Safety Information

Gopan (pantoprazole) is generally well-tolerated, but like all medicines, it is associated with known side effects and specific safety warnings detailed in regulatory documents.

Adverse Reactions

Common adverse reactions (reported in adult trials at ge 2% frequency) primarily involve the gastrointestinal and nervous systems, including headache, diarrhea, nausea, abdominal pain, vomiting, flatulence, dizziness, and joint pain (arthralgia).

Serious and clinically significant adverse reactions are uncommon or rare but warrant immediate attention:

  • Acute Tubulointerstitial Nephritis (AIN): Sudden inflammation of the kidneys, which can occur at any time during treatment.
  • Clostridium difficile-Associated Diarrhea (CDAD): Severe, persistent, or watery diarrhea may be a symptom of CDAD.
  • Bone Fracture: Long-term, high-dose therapy (one year or longer) may increase the risk of fractures of the hip, wrist, or spine, particularly in older adults.
  • Severe Cutaneous Adverse Reactions (SCARs): Rare but life-threatening skin reactions, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
  • Lupus Erythematosus: New onset or exacerbation of existing cutaneous or systemic lupus erythematosus (CLE/SLE).
  • Hypomagnesemia: Low serum magnesium levels, often occurring after prolonged use (at least three months), potentially leading to serious consequences like seizures or arrhythmias.
  • Vitamin B12 Deficiency: Daily use for a prolonged period (typically longer than three years) may lead to malabsorption and deficiency of Vitamin B12.
  • Fundic Gland Polyps: Risk increases with long-term use, especially beyond one year.

Safety Restrictions and Monitoring Notes

Gopan is contraindicated in patients with a known history of hypersensitivity to pantoprazole or any substituted benzimidazoles. It is also contraindicated for use with products containing rilpivirine.

Warnings and Precautions require medical professionals to exclude the presence of gastric malignancy before starting therapy, as symptomatic response to Gopan does not preclude an underlying tumor. Use in patients with severe hepatic impairment requires caution. For pregnant and breastfeeding women, use is only advised if the potential benefit justifies the potential risk. Pediatric use (under 5 years of age) has not established safety and effectiveness for certain indications.

Overdose and Emergency Response

Gopan Overdose and When to Seek Help

Regulatory information concerning acute overdose of Gopan (Pantoprazole) indicates that human experience with massive ingestion is limited. High-dose exposures have generally been reported to be well-tolerated, with a low expectation of severe, life-threatening outcomes noted in official assessments.

Documented Manifestations and Management:

Category Regulatory Statement
Documented Manifestations Symptoms reported are typically consistent with known adverse effects. These may include tachycardia, vomiting, drowsiness, and abdominal pain.
Antidote and Treatment No specific antidote is known. Treatment must be exclusively symptomatic and supportive, necessitating continuous clinical monitoring of the patient's condition.

Required Emergency Actions:

In the event of a suspected overdose or the ingestion of a dose above the therapeutic range, regulatory agencies explicitly mandate two immediate actions. Patients must seek immediate medical attention by contacting emergency services. Additionally, patients should contact a Poison Control Center to report the exposure. Standard procedural measures, such as the administration of activated charcoal or gastric lavage, may be considered by medical professionals. Regulatory documents confirm that the drug is not significantly dialyzable.

Therapeutic Uses of Gopan

Quick Facts: Gopan Therapeutic Use

  • Addresses: Symptoms associated with Gastroesophageal Reflux Disease (GERD).
  • Manages: Erosive esophagitis (inflammation and injury of the food pipe).
  • Supports: The treatment of pathological hypersecretory conditions.
  • Relieves: Heartburn and discomfort related to acid reflux.

What Gopan Treats: Main Uses and Benefits

Gopan is a medication utilized in therapeutic regimens intended to address conditions resulting from excessive stomach acid production. It is indicated for the short-term treatment of erosive esophagitis that is associated with Gastroesophageal Reflux Disease (GERD). This use supports the healing of tissue damage and assists in the management of related symptoms, such as heartburn.

The medication is also utilized to maintain the healing of erosive esophagitis after the initial therapeutic course. Furthermore, Gopan is indicated for the long-term management of pathological hypersecretory conditions, which involve the stomach producing abnormally high levels of acid. A key example of this application is in the care of individuals with Zollinger-Ellison syndrome.

Eligibility and Restrictions for Use

Eligibility for Gopan: Official Regulatory Information

Official regulatory documents define patient eligibility for Gopan through a set of mandatory exclusions (contraindications) and specific population restrictions. Patients who must not use Gopan are those with a documented hypersensitivity to the active substance or any component of the formulation.

Classification Eligibility Status
Pediatric Patients Use is not established or not recommended (typically under 18 years) due to insufficient data on safety and efficacy.
Pregnancy/Lactation Use is often not recommended or contraindicated, depending on the drug's specific risk profile and documented evidence of potential fetal or infant harm.
Severe Organ Impairment Patients with severe hepatic or renal impairment may be contraindicated or not recommended for use, as altered drug clearance can lead to increased toxicity, requiring close monitoring or complete exclusion as specified in the label.

All other individuals who do not present these specified contraindications or limiting conditions are considered eligible for use, pending a comprehensive clinical assessment. Restrictions for geriatric patients may include the need for increased monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Gopan details specific combinations and monitoring requirements based on documented interaction patterns. The primary interaction risk stems from the drug’s profound effect on gastric acidity, which alters the pharmacokinetics of other co-administered substances.

Contraindicated and Prohibited Combinations The co-administration of Gopan is strictly prohibited with certain HIV protease inhibitors, including Atazanavir and Nelfinavir, as this combination significantly reduces the bioavailability and effectiveness of the antiretroviral agents. Co-administration with Rilpivirine-containing products must also be avoided to prevent decreased antiviral efficacy.

Exposure Modification Due to the reduction in gastric acidity, the exposure of medicines dependent on acidic pH for absorption, such as antifungal agents (Ketoconazole, Itraconazole) and certain tyrosine kinase inhibitors, may be reduced. Conversely, co-administration with high-dose Methotrexate may increase the serum concentration of Methotrexate, and the exposure of Saquinavir may be increased, potentially raising toxicity risk.

Monitoring and Other Cautions The co-administration of Gopan and coumarin anticoagulants (e.g., Warfarin) requires specific monitoring of the International Normalized Ratio (INR) due to reports of altered bleeding times. For patients taking drugs that can cause hypomagnesemia, such as diuretics, monitoring of magnesium levels may be warranted during prolonged use. The drug's delayed-release tablets confirm no clinically significant interaction with ethanol (alcohol).

Mechanism of Action

Gopan acts as a prodrug that is selectively activated within the highly acidic environment of the gastric parietal cell's secretory canaliculus. Here, it undergoes acid-catalyzed conversion into a sulfenamide derivative, the active metabolite. This metabolite achieves irreversible covalent inhibition of the H^+/ K^+- ATPase enzyme system (the proton pump) by forming a stable disulfide bond with specific Cysteine residues on the enzyme. This mechanism physically blocks the final step of H^+ ion transfer into the stomach lumen. The irreversible binding dictates the prolonged physiological effect, resulting in a sustained suppression of both basal and stimulated acid secretion independent of the drug's plasma clearance. In combination products, a separate mechanism involving antagonism of peripheral Dopamine D2 receptors modulates gastrointestinal smooth muscle tone, causing a physiological enhancement of gastric emptying and increased lower esophageal sphincter (LES) tone.

Dosage and Administration Information

How to Use Gopan: Administration Guidelines

The usage of Gopan (Pantoprazole) is structured around two routes of administration and indication-specific dosing rules.

Administration Scope

Parameter Instruction
Route of Administration Oral (gastro-resistant tablet) and Intravenous (IV) (reconstituted solution).
Dosing Schedule Standard Dosing: 40 mg once daily for most Erosive Esophagitis (EE) indications. Pathological Hypersecretory Conditions (PHC): Dosing starts at 40 mg twice daily (oral) or 80 mg every 12 hours (IV), adjustable based on acid output, with recorded maximums up to 240 mg per day.
Timing in relation to meals May be taken with or without food.
Preparation Requirements The IV powder is reconstituted (e.g., with 0.9% Sodium Chloride) immediately prior to use.
Age-Group Rules Severe Hepatic Impairment: Daily oral dose generally does not exceed 20 mg. Older Adults and Renal Impairment: No dose adjustment is typically required.
Missed-Dose Rules If a dose is missed, it is typically taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped.

Procedural Constraints

Oral tablets are swallowed whole and are not crushed, split, or chewed due to the specialized gastro-resistant coating. The intravenous administration is intended for short-term use, typically 7 to 10 days, after which patients are transitioned to oral therapy once medically able. IV administration is performed as either a slow injection over at least two minutes or an infusion over approximately 15 minutes.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Gopan

Evidence for Use in Short-Term Treatment of Erosive Esophagitis

Research exploring the use of Gopan for erosive esophagitis (EE), where stomach acid has caused visible injury, has primarily relied on short-term studies, often designed as randomized controlled trials (RCTs). These trials examined outcomes such as rates of tissue repair and monitored patient-reported outcomes describing perceived discomfort and changes in symptoms like heartburn over periods of 4 to 8 weeks. The studies reported patterns where patient-reported outcomes evolved and measurements related to tissue repair were observed in the populations. Research exploring short-term symptom changes contributes to the broader evidence landscape used by regulators. The short-term nature of these trials, however, provides limited insight into the rate of symptom or tissue damage recurrence immediately after the initial treatment is completed.

Evidence for Maintenance of Healing and Relapse Prevention

Once the tissue damage has healed, subsequent research has explored outcomes related to the recurrence of tissue damage and symptoms. Studies for this purpose were designed as long-term randomized trials, often observing patients for up to one year. These trials examined outcomes related to the rate of tissue damage recurrence (relapse). Findings describe patterns related to the stability of the previously repaired tissue over the observed time intervals. However, the follow-up durations for these controlled maintenance studies were limited, meaning long-term effects are not fully established regarding sustained outcomes beyond one year.

Research Gaps and Areas of Uncertainty

While extensive research is available for the short-term treatment of erosive esophagitis, evidence highlights what is known—and what is still uncertain. For instance, comparative evidence is lacking to definitively address whether research has explored if Gopan's patterns of initial symptom relief are distinct from every other medicine in its class. Additionally, data for certain groups remain insufficient, particularly regarding complex outcomes in older adults with co-existing conditions and for rare hypersecretory conditions in groups like children. These research limitation frames mean the results apply only to the populations studied.

Key Studies & References

  1. Maintenance therapy with pantoprazole 20 mg prevents relapse of reflux oesophagitis

Frequently Asked Questions (FAQ)

Common questions about Gopan (FAQ)

Q: What is Gopan used for?

A: Gopan is approved for the management of type 2 diabetes mellitus in adults. It is intended to be used alongside diet and exercise to help improve blood sugar control.

Q: How does Gopan work?

A: Gopan belongs to a class of medications known as SGLT2 inhibitors. It acts on the kidneys to help the body remove excess glucose through the urine, which contributes to lower blood sugar levels.

Q: What are the common side effects of Gopan?

A: The most frequently reported side effects in clinical trials included urinary tract infections, genital yeast infections, and increased urination. Patients who experience side effects should discuss them with their healthcare provider.

Q: Is Gopan a replacement for insulin?

A: Gopan is not a substitute for insulin. It may be used alone or in combination with other anti-diabetic medications, including insulin, as determined by a healthcare professional.

How should Gopan be stored and disposed of?

Official Storage Requirements

All forms of Gopan (Pantoprazole) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted fluctuations. The product must be stored out of the reach of children.

Formulation Key Storage Constraint Stability Time Limit
Oral (Tablets/Suspension) Store away from moisture and light; Do not freeze Up to 6 months after first opening an HDPE bottle.
Intravenous (Injection) Unopened vials require protection from light; Do not freeze solutions Diluted solution must be used within 24 hours of initial reconstitution.

Handling and Disposal

The injection solutions must not be frozen after preparation. If the stability time limit (e.g., 24 hours for the diluted IV solution) is exceeded, the unused portion must be discarded. Disposal of any unused or expired Gopan must be carried out in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagIndia

Equivalent of Gopan found in:

A-Z Index: